Source comparison
Best IGF-1 LR3 Dosage Muscle Growth 2026: Comparison
20–30mcg daily 60–70% saturation Insulin-sensitive subjects, high training frequency, first-time protocols Mild glucose disposal (+15–20% uptake) Low (5–10% of subjects) Optimal starting point for metabolically healthy researchers. Efficacy without metabolic d
This comparison does not assign a generated winner or score.
- 20–30mcg daily
- 60–70% saturation
- Insulin-sensitive subjects, high training frequency, first-time protocols
- Mild glucose disposal (+15–20% uptake)
- Low (5–10% of subjects)
- Optimal starting point for metabolically healthy researchers. Efficacy without metabolic disruption
- 40–50mcg daily
- 80–85% saturation
- Moderate insulin sensitivity, standard training volume, intermediate protocols
- Moderate glucose disposal (+30–40% uptake)
- Moderate (20–30% of subjects)
- Sweet spot for most research contexts. Maximal anabolic signaling before diminishing returns
- 60–80mcg daily
- 90–95% saturation
- Insulin-resistant subjects, low training frequency, advanced recomposition protocols
- Pronounced glucose disposal (+50–60% uptake)
- High (40–50% of subjects)
- Reserved for metabolically compromised subjects or those requiring maximum anabolic drive despite side-effect risk
- >80mcg daily
- Near-complete saturation
- Rarely justified outside extreme research contexts
- Severe glucose disposal (>70% uptake)
- Very high (>60% of subjects)
- Exceeds receptor occupancy ceiling. Additional dose increases systemic insulin-like effects without proportional muscle anabolism
- The comparison table underscores a critical point: dose escalation beyond 50mcg produces minimal incremental muscle protein synthesis benefit while substantially increasing metabolic side-effect burden. Researchers chasing 'more anabolic signal' by pushing to 100mcg+ consistently report hypoglycemic episodes requiring protocol termination.